Cargando…
Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas
Additional prognostic and therapeutic biomarkers effective across different histological types of sarcoma are needed. Herein we evaluate expression of TAZ and YAP, the p53-MDM2 axis, and RABL6A, a novel oncoprotein with potential ties to both pathways, in sarcomas of different histological types. Im...
Autores principales: | Desai, Chandni, Thomason, Jon, Kohlmeyer, Jordan L., Reisetter, Anna C., Ahirwar, Parmanand, Jahanseir, Khadijeh, Leidinger, Mariah, Ofori-Amanfo, Georgina, Fritchie, Karen, Velu, Sadanandan E., Breheny, Patrick, Quelle, Dawn E., Tanas, Munir R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057271/ https://www.ncbi.nlm.nih.gov/pubmed/33889298 http://dx.doi.org/10.18632/oncotarget.27928 |
Ejemplares similares
-
Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo
por: Kohlmeyer, Jordan L, et al.
Publicado: (2022) -
Combination therapies for MPNSTs targeting RABL6A-RB1 signaling
por: Kohlmeyer, Jordan L., et al.
Publicado: (2021) -
RABL6A Promotes Pancreatic Neuroendocrine Tumor Angiogenesis and Progression In Vivo
por: Maharjan, Chandra K., et al.
Publicado: (2021) -
RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner
por: Kohlmeyer, Jordan L., et al.
Publicado: (2021) -
A comprehensive evaluation of Hippo pathway silencing in sarcomas
por: Merritt, Nicole M., et al.
Publicado: (2018)